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Introduction
While the diagnosis of cancer is not common in young men
and women, cancer survivors younger than 40 are likely to
be very concerned about the impact of their cancer on future
fertility, their risk of cancer recurrence after treatment and
risks to future offspring. It is estimated that 1 in 900 persons
between 16 and 44 are cancer survivors [1], and that there are
at least 250,000 women age 40 and younger who are breast
cancer survivors in the United States. As cancer survival
increases, the focus on quality of life issues increases. When
questioned, at least 73% of young breast cancer survivors
reported concerns about infertility due to cancer treatment,
and 29% reported that this concern impacted their choice of
cancer treatment [2].
Premature ovarian failure
In women, the options for preserving fertility and risk of
ovarian failure depends on the age at the time the cancer
is treated, the type and location of cancer, and the specific
treatment chosen. Some treatments, such as bone marrow
transplantation (BMT) are accompanied by very high rates
(>99%) of ovarian failure [3]. Even for those women who
resume normal menstruation after chemotherapy, premature
ovarian failure (POF) is not uncommon [4], and the risk of
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premature ovarian failure is 8-fold higher in cancer survivors
[5]. The risk of POF increases with the woman’s age, with
less than 20% of women under 30 years experiencing POF,
whereas most women older than 40 will become menopausal
after chemotherapy [6].
POF and menopause are dependent on the type of therapy
used. Rates of ovarian failure range from 15% for acute mye-
locytic leukemia (AML) to 50% for breast cancer, with the
overall rate of ovarian failure of 34% [4]. The chemotherapy
agents with the highest risk for ovarian failure were the alky-
lating agents. The higher the dose of these drugs, the higher
the likelihood of ovarian failure.
Ovarian tissue damage is well documented with the use
of radiation therapy. Radiotherapy is used for treatment of
several cancer types affecting pre-menopausal women. The
degree of damage to ovarian tissue is related to a woman’s
age, the total dose of radiation used, and the number of
exposures. In one study, when the same total dose of radiation
was delivered, exposure to multiple fractionated doses versus
a single dose resulted in less damage to the ovaries [4].
When used in conjunction with chemotherapy, the risk of
POF increases. Byrne et al. assessed the risk of premature
ovarian failure in childhood cancer survivors and found the
relative risk of early menopause was 9.2 for those treated with
chemotherapy alone, and 27 for those treated with radiation
plus chemotherapy [5].
Fertility preservation techniques
Although an increasing number of techniques have become
available for the preservation of fertility, many are exper-
imental and have not been tested in randomized controlled
trials. Table 1 reviews the types of options available and their
benefits and limitations.
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Table 1 Fertility preservation options for women with malignancies
Method Benefits Limitations
In vitro Fertilization (IVF) Most successful, widespread Delay of therapy, use of fertility medications
Frozen oocytes No partner is needed Difficult to preserve
Ovarian tissue preservation Less tissue damage from freezing, can be used
in pre-menarchal and young women
Experimental
Transposition of ovarian tissue Less radiation exposure Limited to women having radiation therapy
Pharmacological protection Limit damage to ovarian tissue Adequate prospective studies needed
In vitro fertilization (IVF)
The best-studied and most successful option for preserving
fertility in female cancer patients is ovarian stimulation fol-
lowed by IVF and embryo cryopreservation. Ovarian stimu-
lation needs to occur prior to cancer therapy because treat-
ment can adversely affect ovarian reserve and response. The
pregnancy rate with frozen embryos is lower compared to
fresh IVF embryo transfer. A meta-analysis by the Ameri-
can Society for Reproductive Medicine reviewed over 88000
cycles of assisted reproductive technology (ART) treatment.
When fresh oocytes were used, a delivery rate of 41.8% was
found in more than 6500 cycles analyzed, compared to a
delivery rate of 18.6% for frozen embryos [7].
One concern about ovarian stimulation with IVF is that it
requires a delay of therapy, which could impact growth rate
of tumors and survival rates. In addition, concerns have been
voiced that the medications used to stimulate ovarian pro-
duction could impact on estrogen-receptor positive tumors
such as breast carcinoma. Anti-estrogens, such as tamoxifen,
or aromatase inhibitors, (e.g. letrozole), have both been used
in ovarian stimulation in breast cancer patients to maintain
low estradiol levels during IVF cycles.
Frozen oocytes
Frozen oocytes are more difficult to preserve, resulting in a
lower survival, fertilization and pregnancy rates. Damage is
in part due to ice formation during the freezing process. Un-
fertilized frozen oocytes have a low success rate for live birth
(2% per oocyte) [8], although the rates are now increasing.
Rapid freezing of eggs by vitrification limits damage, which
improves oocyte survival. Using intracytoplasmic sperm in-
jection (ICSI) increases the fertilization rate even further.
Ovarian tissue cryopreservation
For pre-menarchal girls, young women with POF, women
that cannot delay therapy or those in whom high doses of fer-
tility medications are contraindicated, ovarian tissue cryop-
reservation is offered in some centers. Unlike frozen oocytes,
primordial follicles in ovarian tissue are smaller and have less
follicular fluid, and therefore may be at less risk from damage
from ice crystals that form during freezing. It is hoped that
transplanting thawed ovarian tissue will result in the recov-
ery of fertility. Transplantation should be used with caution
in women with ovarian or metastatic cancer, to prevent trans-
ferring malignant cells back after treatment. This treatment
is still considered experimental. Although success in animals
has been demonstrated, transplantation of cryopreserved
ovarian tissue has resulted in only two livebirths [9, 10].
Ovarian transposition
For women having pelvic radiation, transposition of ovarian
tissue outside of the field of radiation successfully preserves
ovarian function. The radiation dose to the transposed ovary
is approximately 5–10% the level of the non-transposed
ovary [11].
Pharmacological protection
To limit or prevent chemotherapy-induced POF, some cen-
ters use gonadatropin releasing hormone (GnRH) agonists
to reduce gonadatropins. This results in mimicking a pre-
pubertal state, because the ovary appears to be less sensi-
tive to gonadotoxic drugs prior to menarche. Because di-
viding cells are more susceptible to damage from cytotoxic
agents, ovarian follicular cells are vulnerable. The mech-
anism of protection by GnRH agonists is unknown. One
prospective clinical case series found that 70 of 75 women
(93%) co-treated with GnRH agonists and chemotherapy re-
sumed cyclic ovarian function verses 38 of 82 women (46%)
treated with chemotherapy alone [12]. Adequately controlled
prospective studies still are required, although data from
animal studies are promising. Anti-apoptotic agents, such
as sphingosine-1-phosphate (SIP), have prevented radiation-
induced oocyte loss in mice [13]. However, since apoptosis
is needed for the treatment of cancer, this method faces some
obstacles for implementation.
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Male fertility
In men, sperm banking is routine and should be offered to all
men prior to undergoing cancer treatment. When combined
with intracytoplamic sperm injection (ICSI), sperm banking
should preserve fertility for almost all males. There is no
increased risk for birth defects when sperm is banked prior
to therapy [14, 15]. Even in azoospermic males, testicular
sperm extraction (TESE) with ICSI has resulted in successful
pregnancies. By 2005, 11 of 29 men with azoospermia that
had used TESE with ICSI had achieved a pregnancy which
resulted in a livebirth [16]. For pre-pubertal males, sperm
banking is not available because there is no spermatogenesis.
The possibility of cryobanking of testicular tissue is being
explored [16, 17]. An increase in sperm aneuploidy is seen
up to 18 months post-chemotherapy, so it has been suggested
that a delay of conception for 12–18 months after therapy is
completed is reasonable [18].
Pregnancy after cancer
Once a woman has recovered from cancer treatment, no
clear guidelines exist about the length of time to wait before
attempting to become pregnant.
Effect of cancer treatment on pregnancy
Once a cancer survivor achieves pregnancy, her health and
the fetal health may be adversely affected by her prior
treatment for cancer. Clinically significant heart disease oc-
curs in 0.5–1% of women treated with anthracycline-based
chemotherapy drugs, and may not develop until months or
years after therapy is completed [19]. Also, women who
have radiation to the left side of the abdomen or chest are
at risk for heart damage, which could worsen during preg-
nancy or labor. Women with radiation to the abdomen or
pelvic area or total body radiation are at increased risk for
miscarriage, preterm birth and delivery of low birthweight
infants [20]. A report from the Childhood Cancer Survivor
Study (CCSS) did not show any increase in adverse preg-
nancy outcomes in women treated with most chemotherapy
agents. However, an increased risk of stillbirth in women
treated with abdominal radiation for Wilm’s tumor has been
noted [21].
Women who have completed treatment for breast
cancer are often placed on selective estrogen receptor
modulators (SERMs) such as tamoxifen to reduce the
incidence of a second cancer. However, tamoxifen use
during pregnancy is to be avoided because it is potentially
teratogenic.
Effect of pregnancy on cancer
Some women are concerned that the hormonal changes from
pregnancy may increase the risk of cancer recurrence, but
pregnancy after breast cancer management does not increase
the risk of cancer recurrence or cancer-related death [22,
23]. However, women who are carriers of BRCA1 or BRCA2
germline mutations and who have had a full-term pregnancy
are at significantly higher risk of developing breast cancer by
age 40 than mutation carriers who do not have children [24].
The risk for breast cancer is increased by 70% in the first
2 years after pregnancy for BRCA2 carriers, but not BRCA1
carriers [25].
Risk to offspring
Since cancer treatment by radiation and many chemotherapy
agents are known to cause DNA mutations, cancer survivors
are often concerned that the treatment may increase the risk
for birth defects, genetic conditions or cancer in their off-
spring. Several studies have found no increased risk of con-
genital abnormalities in the offspring of cancer survivors.
Epidemiologic data from Japanese survivors of the atomic
bomb and their children did not show any evidence for new
mutations. The CCSS also did not find any link between ra-
diation therapy or chemotherapy for childhood cancer and
genetic diseases or birth defects [26, 27].
Risk of cancer in offspring
No increased risk for childhood cancer was identified in
the offspring of childhood cancer survivors, but additional
follow-up is needed [26]. In rare instances, the childhood
cancer may be hereditary, with a risk of passing on the mu-
tated gene to the offspring. Some cancers, such as breast,
colon or ovarian cancer, are more likely to be hereditary
when the cancer occurs at an earlier age. For women with
breast cancer diagnosed prior to age 40 and no other family
history of early breast cancer, the risk of a mutation in one
of the hereditary breast cancer genes, BRCA1 or BRCA2 is
estimated to be at least 13% [28].
Summary
All women should be counseled about the impact of can-
cer treatment on fertility prior to undergoing chemotherapy,
ovarian surgery or BMT, and offered fertility preservation
options, of which ovarian stimulation with IVF is the most
successful. Once women achieve pregnancy, the risk for birth
defects or genetic conditions is not increased because of
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either radiation or chemotherapy. Because treatment options
may increase the risk for adverse pregnancy outcome, review
of therapy records is essential for determining potential risk
to the pregnancy. For most young cancer survivors, fertility
can be preserved and a successful pregnancy achieved, but
discussing these issues prior to treatment is essential.
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